Literature DB >> 31272680

Amnion-derived cells as a reliable resource for next-generation regenerative medicine.

Akihiro Umezawa1, Akihiro Hasegawa2, Momoko Inoue2, Akiko Tanuma-Takahashi2, Kazuhiro Kajiwara2, Hatsune Makino3, Emi Chikazawa3, Aikou Okamoto4.   

Abstract

The placenta is composed of the amnion, chorionic plate, villous and smooth chorion, decidua basalis, and umbilical cord. The amnion is a readily obtainable source of a large number of cells and cell types, including epithelium, mesenchyme, and endothelium, and is thus an allogeneic resource for regenerative medicine. Endothelial cells are obtained from large arteries and veins in the amniotic membrane as well as the umbilical cord. The amnion-derived cells exhibit transdifferentiation capabilities, including chondrogenesis and cardiomyogenesis, by introduction of transcription factors, in addition to their original and potential phenotypes. The amnion is also a source for production of induced pluripotent stem cells (AM-iPSCs). The AM-iPSCs exhibit stable phenotypes, such as multipotency and immortality, and a unique gene expression pattern. Through the use of amnion-derived cells, as well as other placenta-derived cells, preclinical proof of concept has been achieved in a mouse model of muscular dystrophy.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cell-based therapy; Direct reprogramming; Epithelial cell; HLA; Mesenchymal stem cell; Stromal cell

Mesh:

Year:  2019        PMID: 31272680     DOI: 10.1016/j.placenta.2019.06.381

Source DB:  PubMed          Journal:  Placenta        ISSN: 0143-4004            Impact factor:   3.481


  6 in total

1.  Human Amniotic Mesenchymal Stem Cells Inhibit aGVHD by Regulating Balance of Treg and T Effector Cells.

Authors:  Ya Gao; Weiru Li; Xiaoyin Bu; Ying Xu; Shengchun Cai; Jinman Zhong; Meixue Du; Haitao Sun; Liping Huang; Yongjian He; Xiumei Hu; Qifa Liu; Hua Jin; Qian Wang; Baohong Ping
Journal:  J Inflamm Res       Date:  2021-08-16

Review 2.  Characteristics and Therapeutic Potential of Human Amnion-Derived Stem Cells.

Authors:  Quan-Wen Liu; Qi-Ming Huang; Han-You Wu; Guo-Si-Lang Zuo; Hao-Cheng Gu; Ke-Yu Deng; Hong-Bo Xin
Journal:  Int J Mol Sci       Date:  2021-01-19       Impact factor: 5.923

Review 3.  A Review of Placenta and Umbilical Cord-Derived Stem Cells and the Immunomodulatory Basis of Their Therapeutic Potential in Bronchopulmonary Dysplasia.

Authors:  Wai Kit Chia; Fook Choe Cheah; Nor Haslinda Abdul Aziz; Nirmala Chandralega Kampan; Salwati Shuib; Teck Yee Khong; Geok Chin Tan; Yin Ping Wong
Journal:  Front Pediatr       Date:  2021-03-09       Impact factor: 3.418

4.  Computer-assisted surgery with custom prostheses and human amniotic membrane in a patient with bilateral class IV TMJ reankylosis: a case report.

Authors:  Matteo Val; Mirko Ragazzo; Matteo Bendini; Daniele Manfredini; Diletta Trojan; Luca Guarda Nardini
Journal:  Cell Tissue Bank       Date:  2021-06-27       Impact factor: 1.522

5.  Treatment of COVID-19 Pneumonia: the Case for Placenta-derived Cell Therapy.

Authors:  Ekaterine Berishvili; Laurent Kaiser; Marie Cohen; Thierry Berney; Hanne Scholz; Yngvar Floisand; Jonas Mattsson
Journal:  Stem Cell Rev Rep       Date:  2021-02       Impact factor: 5.739

6.  Human amniotic membrane: an improvement in the treatment of Medication-related osteonecrosis of the jaw (MRONJ)? A case-control study.

Authors:  Mirko Ragazzo; Matteo Val; Giulia Montagner; Diletta Trojan; Stefano Fusetti; Luca Guarda Nardini
Journal:  Cell Tissue Bank       Date:  2021-04-15       Impact factor: 1.522

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.